Skip to search formSkip to main contentSkip to account menu

AN-152

Known as: AEZS-108 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

LHRH, lysine(6)-doxorubicin
ZEN-008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies.
2009
2009
Luteinizing Hormone-Releasing Hormone Receptor-Targeted Chemotherapy Using AN-152
The luteinizing hormone-releasing hormone (LHRH; also known as gonadotropin-releasing hormone) receptor can be utilized for… 
Review
2004
Review
2004
Chemotherapy targeted to cancers through tumoral hormone receptors
2003
2003
Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
PURPOSE AND EXPERIMENTAL DESIGN To improve conventional chemotherapy, we developed cytotoxic analogues of luteinizing hormone… 
Highly Cited
2003
Highly Cited
2003
Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
PURPOSE The receptors for luteinizing hormone-releasing hormone receptor (LHRH-R) are found in >50% of human breast cancers… 
Highly Cited
2002
Highly Cited
2002
Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
OBJECTIVE Most human endometrial and ovarian cancers express receptors for luteinizing hormone- releasing hormone. These… 
Highly Cited
2000
Highly Cited
2000
Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
Eighty percent of human ovarian and endometrial cancers express receptors for luteinizing hormone-releasing hormone (LHRH). These… 
1999
1999
Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.
Highly Cited
1997
Highly Cited
1997
Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
BACKGROUND Receptors for luteinizing hormone-releasing hormone (LH-RH) are found in nearly 80% of human ovarian cancers. The… 
Highly Cited
1996
Highly Cited
1996
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Doxorubicin (DOX) and its daunosamine-modified derivative, 2-pyrrolino-DOX, which is 500-1000 times more active than DOX, were… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)